Join to View Full Profile
Walter Reed National Military Medical CenterBethesda, MD 20889
Phone+1 301-295-4771
Fax+1 301-295-4771
Dr. Theeler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2010 - 2012
Madigan Army Medical CenterResidency, Neurology, 2005 - 2009
Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2005
Certifications & Licensure
SD State Medical License Active through 2027
IN State Medical License 2007 - 2017
American Board of Psychiatry and Neurology Neurology
United Council for Neurologic SubspecialtiesNeuro-Oncology
Publications & Presentations
PubMed
- Unexplained cerebral hemiatrophy in a case of astrocytoma, IDH-Mutant, WHO grade 3: a case report and literature review.Alice S Juell, Brett J Theeler
Neurological Sciences. 2025-11-01 - A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon.Cameron Crowell, Ziwen Zhu, Yingxiang Li, Maria L Varela, Quinn Ostrom
NPJ Precision Oncology. 2025-08-14 - Refractory Nausea and Vomiting Due to Central Nervous System Injury: A Focused Review.Stefan Stoica, Christopher Hogge, Brett James Theeler
Life. 2025-06-27
Journal Articles
- Clinical Decision Making in the Era of Immunotherapy for High Grade-Glioma: Report of Four CasesMartha Quezado, Brett J Theeler, Deric M Park, Edjah Nduom, Nancy Garren, Surabhi Ranjan, Kareem A Zaghloul, BioMed Central
Press Mentions
Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIHNovember 18th, 2020
Alexandria Man to Stand up for 24 Hours Straight in Cancer Fundraising ActFebruary 9th, 2020
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206September 20th, 2019- Join now to see all
Professional Memberships
- Member
- Society for Neuro-OncologyMember
- Member
- Adjunct Member, Section on Tumors
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
